Nanoparticles in influenza subunit vaccine development: Immunogenicity enhancement

被引:59
作者
Khalaj-Hedayati, Atin [1 ]
Chua, Caroline Lin Lin [1 ]
Smooker, Peter [2 ]
Lee, Khai Wooi [1 ]
机构
[1] Taylors Univ, Fac Hlth & Med Sci, Sch Biosci, 1 Jalan Taylors, Subang Jaya 47500, Selangor, Malaysia
[2] RMIT Univ, Sch Sci, Dept Biosci & Food Technol, Victoria, Australia
关键词
immunogenicity; influenza vaccine; nanoparticles; subunit vaccine; vaccine delivery; VIRUS-LIKE PARTICLES; MODIFIED PLGA NANOPARTICLES; IMPROVED CROSS-PROTECTION; MATRIX M(TM) ADJUVANT; H1N1; 2009; VACCINE; IMMUNE-RESPONSES; H5N1; BACILLUS-SUBTILIS; DELIVERY-SYSTEM; SAFETY;
D O I
10.1111/irv.12697
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The threat of novel influenza infections has sparked research efforts to develop subunit vaccines that can induce a more broadly protective immunity by targeting selected regions of the virus. In general, subunit vaccines are safer but may be less immunogenic than whole cell inactivated or live attenuated vaccines. Hence, novel adjuvants that boost immunogenicity are increasingly needed as we move toward the era of modern vaccines. In addition, targeting, delivery, and display of the selected antigens on the surface of professional antigen-presenting cells are also important in vaccine design and development. The use of nanosized particles can be one of the strategies to enhance immunogenicity as they can be efficiently recognized by antigen-presenting cells. They can act as both immunopotentiators and delivery system for the selected antigens. This review will discuss on the applications, advantages, limitations, and types of nanoparticles (NPs) used in the preparation of influenza subunit vaccine candidates to enhance humoral and cellular immune responses.
引用
收藏
页码:92 / 101
页数:10
相关论文
共 115 条
  • [1] ALMEIDA JD, 1975, LANCET, V2, P899
  • [2] LIPID BILAYERS AND BIOMEMBRANES
    BANGHAM, AD
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 1972, 41 : 753 - +
  • [3] BARFOOT R, 1989, IMMUNOLOGY, V68, P233
  • [4] Barnier-Quer Christophe, 2013, Pharmaceutics, V5, P392, DOI 10.3390/pharmaceutics5030392
  • [5] Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults
    Ben-Yehuda, A
    Joseph, A
    Zeira, E
    Even-Chen, S
    Louria-Hayon, I
    Babai, I
    Zakay-Rones, Z
    Greenbaum, E
    Barenholz, Y
    Kedar, E
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2003, 69 (04) : 560 - 567
  • [6] Bengtsson KL, 2011, EXPERT REV VACCINES, V10, P401, DOI [10.1586/erv.11.25, 10.1586/ERV.11.25]
  • [7] Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design
    Bessa, Juliana
    Schmitz, Nicole
    Hinton, Heather J.
    Schwarz, Katrin
    Jegerlehner, Andrea
    Bachmann, Martin F.
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2008, 38 (01) : 114 - 126
  • [8] Influenza Epidemiology, Vaccine Coverage and Vaccine Effectiveness in Children Admitted to Sentinel Australian Hospitals in 2017: Results from the PAEDS-FluCAN Collaboration
    Blyth, Christopher C.
    Macartney, Kristine K.
    McRae, Jocelynne
    Clark, Julia E.
    Marshall, Helen S.
    Buttery, Jim
    Francis, Joshua R.
    Kotsimbos, Tom
    Kelly, Paul M.
    Cheng, Allen C.
    Elliott, Elizabeth
    McIntyre, Peter
    Booy, Robert
    Wood, Nicholas
    Britton, Phillip
    Kesson, Alison
    Richmond, Peter
    Snelling, Tom
    Crawford, Nigel
    Gold, Mike
    Kynaston, Anne
    Holmes, Mark
    Dwyer, Dominic E.
    Senenayake, Sanjaya
    Cooley, Louise
    Irving, Louis
    Simpson, Graham
    Korman, Tony
    Friedman, N. Deborah
    Wark, Peter
    Holwell, Anna
    Bowler, Simon
    Upham, John
    Waterer, Grant
    [J]. CLINICAL INFECTIOUS DISEASES, 2019, 68 (06) : 940 - 948
  • [9] Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin
    Bright, Rick A.
    Carter, Donald M.
    Daniluk, Shannon
    Toapanta, Franklin R.
    Ahmad, Attiya
    Gavrilov, Victor
    Massare, Mike
    Pushko, Peter
    Mytle, Nutan
    Rowe, Thomas
    Smith, Gale
    Ross, Ted M.
    [J]. VACCINE, 2007, 25 (19) : 3871 - 3878
  • [10] Exploiting PLGA-Based Biocompatible Nanoparticles for Next-Generation Tolerogenic Vaccines against Autoimmune Disease
    Cappellano, Giuseppe
    Comi, Cristoforo
    Chiocchetti, Annalisa
    Dianzani, Umberto
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (01)